Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1/Phase 2
PALISADES-1
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
- NCT04989803 ↗
- Active, not recruiting
- Kite, A Gilead Company
- Focused
We haven't built an HCP commentary report on PALISADES-1 (KITE-363; KITE-753 in relapsed and/or refractory B-cell lymphoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on PALISADES-1 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Relapsed and/or Refractory B-cell Lymphoma
- Interventions
- Cyclophosphamide; Fludarabine; KITE-363; KITE-753
- Arms
- Phase 1 a/b: KITE-363 · Experimental
- Phase 1 a/b: KITE-753 · Experimental
- Phase 2: KITE-753 · Experimental
- Enrollment
- 247 (estimated)
- Primary outcomes
- Phase 1a: Percentage of Participants Experiencing Adverse Events Defined as Dose-limiting Toxicities (DLTs) After the Infusion of KITE-363 or KITE-753
- Phase 1b: Objective Response Rate (ORR) for KITE-363 and KITE-753 as per investigator's assessment.
- Phase 2: ORR as per central assessment for KITE-753
- Sponsor
- Kite, A Gilead Company
- Start
- Oct 27, 2021
- Primary completion
- Feb 2030 (estimated)
- Results posted
- No
- Registry record
- NCT04989803 · updated Oct 28, 2026